Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS-663513

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to… Expand
Is this relevant?
Review
2015
Review
2015
In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2014
2014
3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al… Expand
Is this relevant?
2013
2013
TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated… Expand
Is this relevant?
Review
2013
Review
2013
Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
3007 Background: CD137 is a member of the TNFR family and functions as a costimulatory molecule. In preclinical studies BMS… Expand
Is this relevant?
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Is this relevant?